APA

Awad M. M., Chu Q. S., Gandhi L., Stephenson J. J., Govindan R., Bradford D. S., Bonomi P. D., Ellison D. M., Eaton K. D., Fritsch H., Munzert G., Johnson B. E. & Socinski M. A. (20171108). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). : Lung cancer (Amsterdam, Netherlands).

Chicago

Awad Mark M, Chu Quincy S-C, Gandhi Leena, Stephenson Joe J, Govindan Ramaswamy, Bradford Daniel S, Bonomi Philip D, Ellison David M, Eaton Keith D, Fritsch Holger, Munzert Gerd, Johnson Bruce E and Socinski Mark A. 20171108. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). : Lung cancer (Amsterdam, Netherlands).

Harvard

Awad M. M., Chu Q. S., Gandhi L., Stephenson J. J., Govindan R., Bradford D. S., Bonomi P. D., Ellison D. M., Eaton K. D., Fritsch H., Munzert G., Johnson B. E. and Socinski M. A. (20171108). An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). : Lung cancer (Amsterdam, Netherlands).

MLA

Awad Mark M, Chu Quincy S-C, Gandhi Leena, Stephenson Joe J, Govindan Ramaswamy, Bradford Daniel S, Bonomi Philip D, Ellison David M, Eaton Keith D, Fritsch Holger, Munzert Gerd, Johnson Bruce E and Socinski Mark A. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). : Lung cancer (Amsterdam, Netherlands). 20171108.